yes but I figured I would post here in case someone did not come across this monograph on twitter TRIL obviously doesn't have this problem w no RBC binding, but they may find enrollment challenging for AML due to effect on platelets, which as you know are often low in AML too (this was addressed on the cc and the FDA is allowing transfusions to meet the 50K requirement). AML might be a case where more dose work for TRIL would be helpful w gradual titration up in dose based on baseline platelets and also perhaps WBC and ANC
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.